New drug cocktail aims to tame a common blood cancer

NCT ID NCT07555470

Recruiting now Disease control Sponsor: Institute of Hematology & Blood Diseases Hospital, China Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study is testing a combination of two drugs, mosunetuzumab and zeprumetostat, in about 80 people with follicular lymphoma, a type of blood cancer. The trial includes patients who are newly diagnosed (with high or low tumor burden) and those whose cancer has come back or stopped responding to treatment. The goal is to see if the combination can shrink tumors and delay the cancer from getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Mosunetuzumab and Zeprumetostat (SHR2554)
What this could lead to: If successful, this combination could offer a more effective treatment option for follicular lymphoma, potentially leading to longer remission without the need for chemotherapy.
What could go wrong: This is an early-phase trial with only 80 participants, so results may not apply to all patients. The combination may cause side effects, and it is not yet known if it will work better than existing therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA

Contacts and locations

Locations

Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
RECRUITING

Tianjin, Tianjin Municipality, 300020, China
Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences
NOT_YET_RECRUITING

Tianjin, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.